Treatment of Mycoplasma pneumoniae-Induced Rash and Mucositis With Cyclosporine

Background: Mycoplasma pneumoniae-induced rash and mucositis (MIRM) is a relatively newly recognized clinical entity that typically presents with predominant mucositis accompanied by variable cutaneous involvement 7-9 days after the onset of prodromal symptoms. There are no evidence-based guidelines for treatment, and current standards of care may include supportive therapy, antibiotics, corticosteroids, and intravenous immunoglobulin . Objective: This case series aims to describe the potential efficacy of cyclosporine A (CsA) in the treatment of MIRM. Methods: The present case series details our use of CsA early in the course of MIRM in 3 pediatric patients. Results: Rapid clinical resolution was observed following CsA therapy. Conclusions: We suggest that early initiation of CsA may be an effective therapeutic option for MIRM.